Myricetin served as antagonist for negatively regulate MRGPRX2 mediated pseudo-allergic reactions through CD300f/SHP1/SHP2 phosphorylation
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110034 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Baowen Dang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Key Laboratory for Tumor Precisio…. Hauptthemen laut MEDLINE: Hypersensitivity. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Xi’an Jiaotong University.
Abstract (Originalsprache)
BACKGROUND: Mas-related G protein-coupled receptor X2 (MRGPRX2) plays a vital role in mast cells (MCs) degranulation and pseudo-allergic reactions. Leukocyte mono-immunoglobulin-like receptor 3 (CD300f) can negatively regulate MCs degranulation. Identification of drug candidates which target CD300f represents a promising prospect in drug development. Myricetin is widely distributed in plants and has been reported to inhibit allergic reactions in OVA-induced murine models. OBJECTIVE: This study aims to determine whether myricetin can activate CD300f to arrest MCs degranulation mediated by MRGPRX2. RESULTS: Myricetin inhibited the allergic mediator and cytokine release triggered by MRGPRX2 in vivo and in vitro. Under C48/80 stimulation, the release of β-hexosaminidase, TNF-α, IL-8 and MCP-1 in CD300f knockdown in LAD2 cells was significantly increased compared with NC-LAD2 cells. Myricetin displayed good structural affinity (KD = 7.21 × 10-5) with CD300f by SPR. Molecular docking results showed that hydrogen bonds were formed between myricetin and CD300f, indicating high binding ability (5.6653). Myricetin can upregulate the phosphorylation of SHP-1 and SHP-2 and dephosphorylation in the MRGPRX2 signaling pathway, involving PLCγ1, AKT, P38, and ERK1/2. CONCLUSION: In the present study, myricetin is identified as an exogenous ligand for CD300f, which negatively regulates MRGPRX2-mediated MCs activation via CD300f to inhibit MCs degranulation and pseudo-allergic reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an…
- College of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China.
- College of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China. Electronic address: taozhang@xjtu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Xi’an Jiaotong University
Zitieren
APA
Dang, B., Hu, S., Zhang, Y., Huang, Y., Zhang, T., & An, H. (2023). Myricetin served as antagonist for negatively regulate MRGPRX2 mediated pseudo-allergic reactions through CD300f/SHP1/SHP2 phosphorylation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110034
Vancouver
Dang B, Hu S, Zhang Y, Huang Y, Zhang T, An H. Myricetin served as antagonist for negatively regulate MRGPRX2 mediated pseudo-allergic reactions through CD300f/SHP1/SHP2 phosphorylation. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110034
BibTeX
@article{Dang2023,
author = {Dang, Baowen and Hu, Shiting and Zhang, Yonghui and Huang, Yihan and Zhang, Tao and An, Hongli},
title = {Myricetin served as antagonist for negatively regulate MRGPRX2 mediated pseudo-allergic reactions through CD300f/SHP1/SHP2 phosphorylation},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110034}
}
EUVIMED